




3:

ge of all the essential acts.

rmation gives you the ial data you need. our widespread netther, organize and 1 a timely manner. re it is published. xed for quick, ly for fast reference.

Place
Stamp
Here





Editorial Consultants and Contributors

Clement A. Weisbecker, RPh, Director of Pharmacy, Wills Eye Hospital, Philadelphia, PA F.T. Fraunfelder, MD, Director, National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR Michael Naidoff, MD, Cornea Service, Wills Eye Hospital, Philadelphia, PA Douglas Rhee, MD, Wills Eye Hospital, Philadelphia, PA Richard Tippermann, MD, Wills Eye Hospital, Philadelphia, PA Vice President of Directory Services: Stephen B. Greenberg Drug Information Specialist: Maria Deutsch, MS, RPh, CDE Director of Product Management: David P. Reiss Editor, Special Projects: David W. Sifton Senior Product Manager: Mark A. Friedman Vice President of Production: David A. Pitler Associate Product Manager: Bill Shaughnessy Director of Print Purchasing: Marjorie A. Duffy National Sales Manager: Dikran N. Barsamian Director of Operations: Carrie Williams National Account Manager, Customized Projects: Manager of Production: Kimberly H. Vivas Anthony Sorce Senior Production Coordinators: Amy B. Brooks, Senior Account Manager: Don Bruccoleri Account Managers: Marion Gray, RPh, Lawrence C. Keary, Dawn B. McCall Jeffrey F. Pfohl, Christopher N. Schmidt, Production Coordinator: Mary Ellen R. Breun Stephen M. Silverberg, Suzanne E. Yarrow, RN Index/Format Manager: Jeffrey D. Schaefer National Sales Manager, Trade Group: Bill Gaffney Senior Format Editor: Gregory J. Westley Director of Direct Marketing: Michael Bennett Index Editors: Johanna M. Mazur, Robert N. Woerner Direct Marketing Manager: Lorraine M. Loening Art Associate: Joan K. Akerlind Promotion Manager: Donna R. Lynn Senior Digital Imaging Coordinator: Shawn W. Cahill **Director, Professional Support Services:** Digital Imaging Coordinator: Frank J. McElroy, III

Mukesh Mehta, RPh Senior Drug Information Specialist:

Thomas Fleming, RPh

Copyright © 1998 and published by Medical Economics Company, Inc. at Montvale, NJ 07645-1742. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. PHYSICIANS' DESK REFERENCE*, PDR*, PDR For Nonprescription Drugs*, PDR For Ophthalmology*, Pocket PDR*, and The PDR* Family Guide to Prescription Drugs* are registered trademarks used herein under license. PDR Companion Guide™, PDR* for Herbal Medicines™, PDR* Medical Dictionary™, PDR* Nurse's Handbook™, PDR* Nurse's Dictionary™, PDR* Atlas of Anatomy™, The PDR* Family Guide Encyclopedia of Medical Care™, PDR* Electronic Library™, and PDR* Drug Interactions, Side Effects, Indications, Contraindications System™ are trademarks used herein under license.

Electronic Publishing Designer: Robert K. Grossman

Fulfillment Managers: Stephanie DeNardi, Kenneth Siebert

Officers of Medical Economics Company: President and Chief Executive Officer: Curtis B. Allen; Vice President, New Media: L. Suzanne BeDell; Vice President, Corporate Human Resources: Pamela M. Bilash; Vice President and Chief Information Officer: Steven M. Bressler; Senior Vice President, Finance, and Chief Financial Officer: Thomas W. Ehardt; Vice President, Directory Services: Stephen B. Greenberg; Vice President, New Business Planning: Linda G. Hope; Executive Vice President, Healthcare Publishing and Communications: Thomas J. Kelly; Executive Vice President, Magazine Publishing: Lee A. Maniscalco; Vice President, Group Publisher: Terrence W. Meacock; Vice President, Production: David A. Pitler; Vice President, Group Publisher: Thomas C. Pizor; Vice President, Magazine Business Management: Eric-Schlett; Senior Vice President, Operations: John R. Ware

ISBN: 1-56363-290-X

Find authenticated court documents without watermarks at docketalarm.com.

ing family of PL 00-232-7379 or f

netics (FD&C) Act, 3 labeled, promote or only those uses f ess have been esta ations 201.100(d)(in products require Jesk Reference F , dosages, route on of administratic s, contraindication st be in the "san oved labeling for ti same language a se of the approve

Furthermore, inft s emphasized by ti s, boldface, or italk in Physicians' De:

FD&C Act does no physician may use: ; been approved i e it for uses or lations that are n A also observes the des drug use that g. For products th s, the publisher hi bing such produc have access to a id informed decisit er-the-counter dieta ed that this inform he Food and Dr. 3 are not intended lisease.

ompilation, organi tion. Each produ e manufacturer, a ufacturer's medic medical consultat terial in Physician e publisher does f ducts described, connection with a herein. Physician es not assume, a obtain and inclui wided to it by t I that by making th advocating the us or is the publish lue to typographic ly product may

Δ

CONTENTS

Section 1: Indices

	and the second se
1. Manufacturers' Index	
2. Product Name Index	
3. Product Category Index	
4. Active Ingredients Index	

Section 2: Pharmaceuticals in Ophthalmology

1. Mydriatics and Cycloplegics	2
2. Antimicrobial Therapy	
3. Ocular Anti-inflammatory Agents	
4. Anesthetic Agents	
5. Agents for Treatment of Glaucoma	
6. Medications for Dry Eye	
7. Ocular Decongestants	
8. Ophthalmic Irrigating Solutions	
9. Hyperosmolar Agents	
10. Diagnostic Agents	16
11. Viscoelastic Materials Used in Ophthalmology	
12. Off-Label Drug Applications in Ophthalmology	
13. Ocular Toxicology	

Section 3: Suture Materials

Page 23

Section 4: Ophthalmic Lenses	Page 25
1. Soft Contact Lenses	
2. Aphakic Lenses	
3. Comparison and Conversion Tables	52
Section 5: Vision Standards and Low Vision	Page 56
1. Vision Standards	
2. Low-Vision Aids	58
Section 6: Evaluation of Permanent Visual Impairment	
evention of Lyanation of Fernanent Visual impairment	59
1. Criteria and Methods	

DOCKE Δ Find authenticated court documents without watermarks at docketalarm.com.

Page 1

Page I

61

- 1. Index
 102

 2. Full-Color Product Photographs
 103
- Section 8: Pharmaceutical and Equipment Product Information

Listed alphabetically by manufacturer

Section 9: Intraocular Product Information

Key to Controlled Substances Categories

Key to FDA Use-in-Pregnancy Ratings

Amsler's Grid

Inside Front Cover

Page 101

Page 201

Page 315

Page 319

Page 320

SECTION 1

This section offers f mation you need:

1. Manufacturers' participating manuf two page numbers graphs in the Proc ond to product i addresses and tele headquarters and re

2. Product Name I uct information alp mond symbol to the tograph of the Identification Guide page number refers

PART I/MANUF

AKORN, INC. 2500 Millbrook Driv Buffalo Grove, IL 6C Direct Inquiries to: Customer Service (800) 535-7155

ALCON LABORATOR

and its Affiliates Corporate Headqua 6201 South Freewa Fort Worth, TX 761 **Direct inquiries to:** Ophthalmic/VisionC (Pharmaceuticals/L Surgical: (800) 862 (Instrumentation/S Systems: (800) 28 (Medical Managem Systems)

ALLERGAN

2525 Dupont Drive P.O. Box 19534 Irvine, CA 92623-9 **For Medical Inform** Outside CA: (800) CA: (714) 246-45C **Sales and Orderin** Outside CA: (800) CA: (714) 246-45C

BAUSCH & LOMB . PHARMACEUTI(8500 Hidden Rive

Tampa, FL 33637

Find authenticated court documents without watermarks at docketalarm.com.

6. MEDICATIONS FOR DRY EYE

Dry eye refers to a deficiency in either the aqueous or mucin components of the precorneal tear film. The most commonly encountered aqueous-deficient dry eye in the United States is keratoconjunctivitis sicca, while mucin-deficient dry eyes may be seen in cases of hypovitaminosis A, Stevens-Johnson syndrome, ocular pemphigoid, extensive trachoma, and chemical burns.

Dry eye is treated with artificial tear preparations (see Table 20) and ophthalmic lubricants (see Table 21). The lubricants form an occlusive film over the ocular surface and protect the eye from drying. Administered as a nighttime medication, they are useful both for dry eye and in cases of recurrent corneal erosion.

TABLE 20

SET/DURATION

ACTION

min/5-6 h

60 min/6 h

45 min/5-6 h

ARTIFICIAL TEAR PREPARATIONS

ONSET/DURATION	MAJOR COMPONENT(S)	CONCENTRATION (%)	TRADE NAME	PRESERVATIVE/EDTA*
ONSET/DURATION OF ACTION 2 h/4-6 h	Carboxymethyl cellulose	0.5% 1% 0.25%	Refresh Plus Celluvisc Theratears	None None None
	Glycerin	3%	Dry Eye Therapy	None
510 min/2 h	Hydroxyethyl cellulose, polyvinyl alcohol		TearGard	Sorbic acid, EDTA
 30 min/6 h	Hydroxypropyl cellulose		Lacrisert (biode- gradable insert)	None
 2 h/4–6 h	Hydroxypropyl methylcellulose	0.5%	Isopto Plain Isopto Tears Tearisol Isopto Alkaline	Benzalkonium chloride Benzalkonium chloride Benzalkonium chloride, EDTA Benzalkonium chloride
- 10	Hydroxypropyl methylcellulose, dextran 70		Bion Tears Ocucoat Ocucoat PF Tears Naturale II Tears Naturale Free Tears Renewed	None Benzalkonium chloride, EDTA None Polyquad None Benzalkonium chloride, EDTA
SIZE(S)(mL)	Methylcellulose	1%	Murocel	Methyl-, propylparabens
5 single use bottle	Polycarbophil, PEG-400, dextran 7	0	AquaSite AquaSite multi-dose	EDTA EDTA, Sorbic acid
5, 10, 15	Polysorbate 80		Viva Drops	EDTA
- 165	Polyvinyl alcohol	1.4% 3%	AKWA Tears Dry Eyes Liquifilm Tears	Benzalkonium chloride, EDTA Chlorobutanol Chlorobutanol
SIZE(S)(mL)	Polyvinyl alcohol, PEG-400, dextrose	1%	HypoTears HypoTears PF Puralube Tears	Benzalkonium chloride, EDTA EDTA Benzalkonium chloride, EDTA
2.5	Polyvinyl alcohol, povidone	1.4% 0.6%	Murine Tears Refresh Tears Plus	Benzalkonium chloride, EDTA None Chiorobutanol

*EDTA = ethylenediaminetetraacetic acid.

DOCKE Δ

Find authenticated court documents without watermarks at docketalarm.com.

14 / PDR FOR OPHTHALMOLOGY

TABLE 21

OPHTHALMIC LUBRICANTS

TRADE NAME	COMPOSITION OF STERILE OINTMENT
AKWA Tears Ointment	White petrolatum, liquid lanolin, and mineral oil
Dry Eyes	White petrolatum, liquid lanolin, and mineral oil
Duolube	White petrolatum and mineral oil
Duratears Naturale	White petrolatum, liquid lanolin, and mineral oil
HypoTears	White petrolatum and light mineral oil
Lacri-Lube S.O.P., Lubritears	42.5% mineral oil, 55% white petrolatum, lanolin alcohol, and chlorobutanol
Puralube	White petrolatum, liquid lanolin, and mineral oil
Refresh P.M., Dry Eyes Lubricant	41.5% mineral oil, 55% white petrolatum, petrolatum, and lanolin alcohol

7. OCULAR DECONGESTANTS

These topically applied adrenergic medications are commonly used to whiten the eye. Three types are available. Those containing naphazoline and tetrahydrozoline are more stable than those with phenylephrine. Usual dosage is 1 or 2 drops no more than 4 times a day (see **Table 22**).

TABLE 22

DOCKET

Δ

OCULAR DECONGESTANTS

DRUG	TRADE NAME	ADDITIONAL COMPONENTS
Naphazoline hydrochloride	AK-Con*	Benzalkonium chloride, edetate disodium
	Albalon*	Benzalkonium chloride, edetate disodium
	Clear Eyes	Benzalkonium chloride, edetate disodium
	Naphcon	Benzalkonium chloride, edetate disodium
	Vasoclear	Benzalkonium chloride, edetate disodium
	Vasocon Regular*	Phenylmercuric acetate
Oxymetazoline hydrochloride	Visine L.R.	Benzalkonium chloride, edetate disodium
	Ocuclear	Benzalkonium chloride, edetate disodium
Phenylephrine hydrochloride	AK-Nefrin	Benzalkonium chloride, edetate disodium
	Eye Cool	Thimerosal, edetate disodium
	Prefrin Liquifilm	Benzalkonium chloride, edetate disodium
	Relief	_
Tetrahydrozoline hydrochloride	Collyrium Fresh	Benzalkonium chloride, edetate disodium
	Murine Plus	Benzalkonium chloride, edetate disodium
	Visine	Benzalkonium chloride, edetate disodium
DECONGESTANT/ASTRINGENT COMBINATIONS		
Naphazoline hydrochloride	Clear Eyes ACR	Benzalkonium chloride, edetate disodium
plus zinc sulfate	(allergy/cold relief)	
Phenylephrine hydrochloride		E
plus zinc sulfate	Zincfrin	Benzalkonium chloride
Tetrahydrozoline plus zinc sulfate	Visine Allergy Relief	Benzalkonium chloride, edetate disodium

8. OPHTHA

Listed in **Table 23** general ophthalmic products. There ar tions available for

TABLE 23

OPHTHALMIC II

TRADE NAME

AK-Rinse

Collyrium Fresh Eyes

Dacriose

Eye-Stream

Irigate

Lavoptik Eye Wash

9. HYPER

Hyperosmolar (hy They act through

TABLE 24

HYPEROSMO

GENERIC NAME

A. Therapeutic prepa Sodium chloride

B. Diagnostic prepa Glycerin

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.